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A B S T R A C T
Traditional medical practice has suffered from male bias, which can lead to sub-optimal treatment options for
female patients and increase the incidence of severe side-effects in this population. Mobile health applications,
mHealth apps, represent one essential component of the shift towards consumer-centered self-administered
individualized health. To prevent sex-specific bias it is important that trials consider sex and gender when
developing mHealth apps. We evaluated the inclusion and reporting of sex and gender at all levels in mHealth
randomized controlled trials (RCTs). To this end, we conducted a secondary analysis of a large study database
addressing the effectiveness of app interventions on clinical outcomes in patients with chronic medical condi-
tions. We followed the 5 steps described in the framework by Arksey and O’Malley and the guidelines of the
PRISMA-ScR. Of the 72 app-based RCTs which reported information about sex overall, 62 included individuals of
both sexes. The concept of gender was not addressed in any of the studies. The consideration of sex aspects in the
design, execution and reporting of mHealth RCTs was minimal or absent. To adequately address the health and
preventative needs of the mHealth user population, sex and gender should be systematically included in the
research, development and evaluation of mHealth applications.
1. Introduction
Traditional medical practice has suffered from a male bias that can
lead to sub-optimal treatment options and a higher incidence of, po-
tentially deadly, side-effects in the female patient population [1,2]. The
reporting of sex and gender-related data is increasing in the medical
literature over time, but substantial variations still exist between
disciplines. [3]. Nevertheless, sex and gender are increasingly re-
cognized as health modulators in the (bio)medical field. The impact of
sex and gender on the development, diagnosis, treatment and long-term
effects of diseases is now well documented [4,5]. Since funding agen-
cies are calling for sex/gender-sensitive research [6,7] and scientific
journals are applying more stringent criteria to its reporting [8,9], re-
searchers are prompted to engage with the subject more thoroughly.
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Health data is increasingly collected via smartphones and portable
devices (so-called wearables) and can be shared with physicians and
other health service providers [10]. Mobile health applications,
mHealth apps, represent one essential component of the shift towards
consumer-centered self-administered individualized health. Digital in-
terventions could provide low entry barriers [11]. This is of special
importance for patients with conditions that can be associated with
shame, such as mental illnesses, reproductive issues, or cancer.
Sex and gender differences in digital literacy [12], use [13,14] and
preferences [15] of mHealth apps, as well as online health information
seeking [16,17] have been previously reported. Overall, women tend to
report more eHealth and mHealth usage compared to men, but this
seemed to be limited to high-income countries [18]. Regardless of these
reports, gender-sensitive design is rarely applied in developing mHealth
applications and generally limited to female-specific topics [19], such
as menstruation, fertility and reproduction. The neglect of sex-specifi-
city upon content development, as well as a lack of gender-sensitivity
upon product design might represent significant risk factors for the
safety, applicability and market value of the final product. For instance,
when apps employ historical clinical data, which underrepresents
women, they might perpetuate sex-biased medicine if they use un-
differentiated algorithms to mine this data. This might reproduce, e.g.
the under-diagnosis of coronary heart disease in women [20]. Gender,
on the other hand, might impact the type of product chosen and the
access to it. Gender differences in economic means might make some
services unavailable for women, especially in low-income countries
[21], and overly stereotypical designs for women, i.e. “pink it and
shrink it” might dissuade significant consumer fractions. Given these
potential risks, the inclusion of sex and gender aspects in the develop-
ment and execution of trials in the field of digital health appears of
importance.
To our knowledge, no previous study has investigated the inclusion
of sex and gender aspects in app-based RCTs or mHealth trials. The
present study builds upon a previously developed meta-analysis data-
base, assembled by the present authors, on the efficacy and effective-
ness of randomized controlled trials for smartphone app-based inter-
ventions for chronic medical conditions (PROSPERO registration:
CRD42019120119) [22]. The analysis of sex and gender did not fall
within the scope of the original meta-analysis concept, but the rigor-
ously selected literature provided the ideal data basis for a focused
secondary analysis.
To provide a descriptive overview of sex and gender-related aspects,
the following research questions have been formulated: Do women or
men participate more often in smartphone app-based RCTs for chronic
medical conditions? Is sex or gender considered during sample size
calculation in app-based studies for chronic medical conditions? Do
app-based RCTs for chronic medical conditions present sex or gender-
based outcome data and sex or gender-based user behavior data (ad-
herence, satisfaction and usage data)?
2. Methods
Based on our meta-analysis database [22], we performed a sec-
ondary analysis of data following the 5 steps described in the scoping
review framework by Arksey and O’Malley and the guidelines of the
PRISMA-ScR [23,24]. Data were not quantitatively aggregated, but
descriptively summarized [24].
2.1. Data collection
We examined the data extraction work for the meta-analysis of our
team by Barth et al. [22]. For preparation of the meta-analysis data-
base, a first literature search was done in October 2016 and an update
of the search was conducted in March 2019. No publication period or
language limiters were used. Databases searched were PubMed, Web of
Science, PsycINFO and CINAHL.
The following search terms were used: smartphone and its synon-
ymous words (“mobile phone”, smart-phone, cellphone, cell-phone,
“Smartphone”[MeSH], “Cell Phones”[MeSH]), “Mobile
Applications”[MeSH],” mobile app”, Intervention [tiab], treatment
[tiab], therap, RCT [tiab], trial [tiab], random [tiab], control [tiab],
“Randomized Controlled Stud”, “Clinical Stud”, “clinical trial”,
“Random Allocation”, “Treatment Outcome”.
Detailed methods of our meta-analysis can be found in the PROS-
PERO registration database [22]. For the secondary analysis, sex and
gender-related data were extracted, categorized and summarized from
the included trials.
2.2. Eligibility criteria
To be included in the meta-analysis database, studies had to be
smartphone app-based RCTs with an outcome assessment for partici-
pants with chronic medical conditions; the app had to be the main trial
intervention, minimum of number of participants had to be 30 (two-
armed) or 45 (three-armed).
We excluded the following studies: mHealth interventions delivered
by apps aiming at health promotion in participants with risk factor/
behavior (rather than ICD-10 diagnosed patients); studies investigating
apps only as an add-on intervention of a comprehensive face to face
intervention; apps created as a diagnostic tool for participants; apps
implemented in tablets or PDA or web-based platforms (i.e. Facebook
app).
In the secondary analysis investigating sex and gender-specific re-
porting we included all trials that reported sex or gender-related
numbers of study participants. We excluded studies not reporting sex
proportion of participants at baseline. Studies conducted for single-sex
patients (either women only or men only) were excluded from the
secondary analysis, but listed separately for recording purposes.
2.3. Screening process
Three independent researchers (KE, JW, CK) screened titles/ab-
stracts for potential eligibility and full-texts based on inclusion and
exclusion criteria. Disagreement were solved by consensus discussion
with one senior researcher (JB).
Gender-related data were extracted by one author (JW) using a
structured form, the accuracy of data extraction was checked by an-
other author (IG), the identified discrepancies were resolved through
consensus discussion between the two raters supported by the senior
researchers (DP and SOP).
2.4. Data charting process
2.4.1. Data extraction form
A data-charting form was developed by one of the authors (JW) to
determine variables for extraction. Two senior researchers (DP and
SOP) checked and verified the form. Another reviewer (IG) tested the
form with a small subset of included studies. The following data items
were extracted from the studies: author(s), year of publication, country
of origin, study population, sample size, gender distribution, factors
considered during sample size calculation, gender-related primary
outcome data, adherence data, satisfaction data, usage data, gender-
related adherence, satisfaction and usage data.
For this study any sex and gender-related primary outcome data was
included, without having to be pre-defined as primary outcome vari-
able.
2.4.2. Data items definitions
We focused on the extraction of adherence and satisfaction data of
the study app only. We did not include items that focused on adherence
and satisfaction to the treatment.
Definitions for data categories of adherence and satisfaction were
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iteratively defined during the charting process. Data was categorized as
“satisfaction” data when studies described users’ feeling about- or ex-
perience with the study app. Data was categorized as “adherence” data
when studies reported the amount of time that the study app was used
or compliance rates for the study app. Data was categorized as “usage”
data when the data aimed at reporting “engagement with app”, “system
usability score (SUS)”, "app utilization rate", “total number of clicks”.
2.5. Data summary and synthesis
The concept of sex and gender-related data in app studies were
structurally identified and categorized. Study characteristics were re-
ported using table and chart. Gender-related primary outcome and
gender-related user pattern (adherence and usage of the study app), as
well as satisfaction data were extracted and reported in descriptive
statistics.
3. Results
3.1. Study selection and characteristics
The search strategy yielded 10,711 potential manuscripts. After
removing duplications (n = 2854) and eliminating by a first pass
through the titles and abstracts, 289 potentially relevant studies were
included. Screening the full-text and applying eligibility criteria re-
sulted in 72 studies. Of those 72 studies 10 studies were excluded based
on the following criteria: one study on Parkinson’s disease [25] did not
report mean age and sex proportion of the participants; eight studies
[26–33] with 1182 women included only female participants (breast
cancer, asthma control in pregnancy, stress urinary incontinence,
women with chronic widespread pain, etc.); one study developed for
prostate cancer patients [34] included 100 male participants. In the
remaining 62 studies recruiting both male and female participants (n =
8736), the percentage of female participants was slightly lower (n =
4006, 46%) than the percentage of male participants (Fig. 1).
The included app-based studies focused on various diseases: 19 out
of 62 studies investigated people with diabetes (type 1 or type 2); 14
studies patients with hypertension and cardiovascular disease (CVD)
(heart failure, myocardial infarction, coronary heart disease, etc.); 11
studies focused on participants with mental disorder (dispersion, PTSD,
schizophrenia, etc.); 4 studies addressed cancer patients; 5 studies were
developed for respiratory and pulmonary disease (asthma, allergic
rhinitis, COPD); 2 app-based trials investigated Parkinson’s disease; 1
study app was designed for pain; 8 studies were conducted for patients
with other medical conditions, including survivors of critical illness
(patients from adult medical, cardiac and surgical ICUs), insomnia,
chronic hepatitis B, rehabilitation after lumbar spinal surgery, patients
with musculoskeletal conditions, colorectal polyps, psoriasis and stoma.
An overview of study characteristics is presented in Table 1. Ad-
ditionally, a quantitative overview of the target disease conditions of
the app-based RCTs is presented in Fig. 2. Numbers may overlap be-
cause two studies focused on more than one category of disease.
3.2. Terminology
There is an ongoing discussion in the research community about the
definition and reporting of sex and gender in health research. In the
current study we worked with information from health apps, which
employed mostly self-reported data. We do not have access to the
wording of the specific questions asking participants to describe their
identity. For the purpose of this study we assumed that in most cases a
single question asking individuals to identify as female/male was em-
ployed. None of the reported studies paid specific attention to the
concept of gender and no additional information about its potential
analysis was available. Therefore, we chose to refer to all of the data as
sex-specific in the further reporting. We acknowledge that gender
(identity, norms and relationships) might play a role in the choice and
use of these applications, but the included manuscripts did not offer
methodological options to assess this in a robust manner.
3.3. Sample size calculation
The mean sample size of the studies was 140.9 (SD = 115.6), with a
range from 30 to 626 participants. The sample included 10 trials with
larger sample sizes, equal to or exceeding 200 participants. A total of 47
studies reported the sample size calculation methods, none of them
explicitly considered sex during sample size calculation. Estimated ef-
fect on primary outcome, standard deviation, power, and dropout-rate
were the main factors considered during sample size calculation.
3.4. Primary outcome and sex-related data
Among the 62 studies including both male and female participants,
4 (6%) provided sex-related primary outcome data [35–38]. One study
addressing type 1 diabetes [35] reported that “greater HbA1c reduction
was obtained in… male gender…”. Another study focusing on blood
pressure control [36] reported “gender appeared to influence home self-
measured BP…”. A study investigating Parkinson’s disease [37] re-
ported, "females… tend to benefit more… (from the study interven-
tion)". A study conducted for diabetes patients against diabetes-related
distress and depression [38], reported: “we found no overall effect of
the intervention on diabetes distress or depression, nor did we find
treatment differences by sex…”.
3.5. Satisfaction, adherence and usage and sex-related data
In total 29 out of 62 studies (47%) reported adherences data of the
study app, 2 (3%) trials [37,39] provided sex-specific data. A study
aiming at the stimulation of physical activity among COPD patients
[39] reported that “dropout… was also higher among females.” An-
other study (2%) for Parkinson’s patients [37] reported “there was an
indication that women were more adherent than men, but this was not
statistically significant.” 20 studies (32%) reported overall satisfaction
data, however, no sex and gender-related satisfaction data was re-
ported. Altogether, 35 studies (56%) reported usage of the corre-
sponding study app but no sex-disaggregated usage data was reported.
4. Discussion
To the best of our knowledge this secondary analysis of our meta-
analysis database provides the first overview of the consideration of sex
and gender as a primary variable in RCTs investigating mHealth for
chronic medical conditions. We found that the participation rate of
women in the app-based RCTs for chronic medical conditions was
generally slightly lower than that of men. None of the included studies
defined the performance of sex-disaggregated analysis and the provi-
sion of sex-disaggregated results as study objectives. Sex was rarely
considered during sample collection, and was not considered upon
power calculation for the following analysis. Only four studies reported
sex-specific considerations related to the primary outcome and only two
provided sex-specific data on adherence. Overall, the consideration of
sex-specific data in development and reporting of mHealth RCTs for
chronic medical conditions is minimal or absent. The concept of gender
was not addressed in any of the studies.
Our results indicate a neglect of sex-specific data at different levels.
Sex has been ignored as a medically-relevant variable from a content
perspective, but it is also being ignored as a primary element for the
methodological robustness of clinical trial performance and reporting.
Ignoring sex as a biological variable will affect the reliability and
possibly the safety of the product. Sex differences correlate with risk
factors [40] and should thus be considered in designing algorithms for
disease management and prevention. Sex differences impact symptoms
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of disease, such as in the case of coronary artery disease, asthma and
Parkinson´s disease [41]. Also, sex differences correlate with the in-
cidence of pharmacological side effects and need to be considered in the
long-term management of chronic diseases. Since diagnostic support
and long-term management are some of the main goals of mHealth
applications with a clinical focus, neglecting sex aspects in their design
will represent a crucial risk.
The current results also point to the disregard of sex as a primary
factor for the increase of robustness and reproducibility of clinical
trials. RCTs are considered the gold standard for quantitative evaluation
in medicine; their methodological standards should be the highest
compared to other types of study designs. The included manuscripts did
not allow for sex-disaggregated analysis in most cases, since this was
not considered upon power calculation. Regardless of the content of the
study, RCTs should disaggregate their analyses and reporting by sex to
increase transparency, avoid statistical fallacies and facilitate future
meta-analyses [42]. Additionally, only 38 (61%) of the studies overall
reported a power calculation. The number of included participants was
often too low to allow for any stratified analysis. This might not just be
problematic for sex-disaggregation, but potentially for all relevant
subgroup analyses.
Another interesting finding was that 9 out of the 72 (13%) identified
app-based RCTs were conducted for single-sex (either female only or
male only) patients. Eight trials were designed only for women, i.e.
women with widespread pain, breast cancer, and stress urinary incon-
tinence, one trial was developed for men with prostate cancer. This
might point to an increased focus on women´s health in digital
interventions and mHealth research.
We performed the first secondary analysis on the inclusion of sex
and gender in RCTs investigating mHealth apps for chronic medical
conditions. To comprehensively identify all the sex and gender-relevant
data, we followed the 5 steps of the scoping review guideline to extract
and evaluate data on sex-related inclusion, analysis and patterns of use.
This study focuses only on mHealth studies using smartphone applica-
tions for chronic medical conditions. This represents a specific subgroup
of mHealth applications and results might have been different for
eHealth studies, including web-based interventions. Furthermore, we
included studies published until March 2019. Given the current dy-
namic in the research fields of sex and gender-sensitive medicine and
digital health, more recent studies might have placed more attention on
the subject. It is, however, unlikely that the dynamics completely
shifted in the last 12 months.
Overall, we identified a very limited attention for sex and gender in
this specific field of mHealth, which can bear several risks for the users.
Sex differences can potentially affect prediction accuracy and efficacy
of the apps, while gender aspects can influence behavioral change and
usage patterns as well as adherence to mHealth application use. To fill
the existing knowledge-gap in this area, we encourage researchers in
the field of digital health, and especially mHealth, to include sex and
gender into their research and practice. Sex and gender should be
systematically considered when designing clinical trials. Sample sizes
need to be adequately powered to allow for stratified subgroup ana-
lyses. Furthermore, sex and gender-disaggregated data needs to be
collected, analyzed and reported when performing these trials. We
Fig. 1. Flow chart.
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Table 1
Study characteristics and percentages of female participants (ascending publication year).
Author, year Country Target Disease Participants, N Female Participants, n (%)
Quinn et al. 2011 USA diabetes 163 82 (50.3%)
Seto et al. 2012 Canada hypertension and CVD 100 21 (21%)
Kirwan et al. 2013 Australia diabetes 72 44 (61.1%)
Orsama et al. 2013 Finland diabetes 48 22 (45.8%)
Rossi et al. 2013 Italy diabetes 127 67 (52.8%)
Holmen et al. 2014 Norway diabetes 151 62 (41.1%)
Mendelson et al. 2014 France Hypertension and CVD 107 18 (16.8%)
Tabak et al. 2014 Netherlands respiratory and pulmonary disease 30 11 (36.7%)
Varnfield et al. 2014 Australia hypertension and CVD 94 12 (12.8%)
Cingi et al. 2015 Turkey respiratory and pulmonary disease 228 116 (50.9%)
Drion et al. 2015 Netherlands diabetes 63 23 (36.5%)
Faurholt-Jepsen et al. 2015 Denmark mental disorder 67 45 (67.2%)
Karhula et al. 2015 Finnland diabetes; hypertension and CVD 519 202 (38.9%)
Skrøvseth et al. 2015 Norway diabetes 30 19 (63.3%)
Van der Weegen et al. 2015 Netherlands respiratory and pulmonary disease; diabetes 199 102 (51.3%)
Arean et al. 2016 USA mental disorder 626 494 (78.9%)
Johnston et al. 2016 Sweden hypertension and CVD 166 32 (19.3%)
Jeon et al. 2016 Korea other 53 5 (9.4%)
Quinn et al. 2016 USA diabetes 118 59 (50%)
Vorrink et al. 2016 Netherlands respiratory and pulmonary disease 157 79 (50.3%)
Wang et al. 2016 China other 203 74 (36.5%)
Baron et al. 2017 UK diabetes 81 35 (43.2%)
Bender et al. 2017 USA diabetes 45 28 (62%)
Christoforou et al. 2017 UK mental disorder 142 118 (83.1%)
Dang et al. 2017 USA hypertension and CVD 61 22 (36.1%)
Del Rosario et al. 2017 Australia hypertension and CVD 66 24 (36.4%)
Horsch et al. 2017 Netherlands other 151 94 (62.3%)
Kerfoot et al. 2017 USA diabetes 456 28 (6.1%)
Kleinman et al. 2017 India diabetes 90 27 (30%)
Kuhn et al. 2017 USA mental disorder 120 83 (69.2%)
Lambert et al. 2017 Australia other 80 52 (65%)
Lakshminarayana et al. 2017 UK Parkinson's disease 201 79 (39.3%)
Mantani et al. 2017 Japan mental disorder 164 87 (53.1%)
Quinn et al. 2017 USA diabetes 114 56 (49.1%)
Sun et al. 2017 Denmark cancer patients 46 14 (30.4%)
Widmer et al. 2017 USA hypertension and CVD 71 13 (18.3%)
Agarwal et al. 2018 Canada diabetes 223 106 (47.5%)
Ben-Zeev et al. 2018 USA mental disorder 163 67(41.1%)
Cox et al. 2018 USA other 80 35 (43.8%)
Di et al. 2018 China cancer patients 132 49 (37.1%)
Ellis et al. 2018 USA Parkinson's disease 51 23 (45.1%)
Hur et al. 2018 Korea mental disorder 34 30 (88.2%)
Krzystanek et al. 2018 Poland mental disorder 290 116 (40%)
Kwon et al. 2018 Korea respiratory and pulmonary disease 85 15 (17.6%)
Lakshminarayan et al. 2018 USA hypertension and CVD 50 14 (28%)
Lüdtke et al. 2018 Germany mental disorder 88 69 (78.4%)
Mayer et al. 2018 USA cancer patients 284 147 (51.8%)
Márquez Contreras et al. 2018 Spain hypertension and CVD 148 77 (52%)
Morawski et al. 2018 USA hypertension and CVD 411 247 (60%)
Ormel et al. 2018 Netherlands cancer patients 32 4 (12.5%)
Santo et al. 2018 Australia hypertension and CVD 163 20 (12.3%)
Sarfo et al. 2018 Ghana hypertension and CVD 60 21 (35%)
Svendsen et al. 2018 Netherlands other 134 52 (38.8%)
Choi et al. 2019 Korea pain 84 57 (67.9%)
Contreras et al. 2019 Spain hypertension and CVD 148 77 (52%)
Donker et al. 2019 Netherlands mental disorder 193 129 (66.8%)
Höchsmann et al. 2019 Switzerland diabetes 36 8 (22.2%)
Hou et al. 2019 China other 168 90 (53.6%)
Lee et al. 2019 Korea other 65 26 (40%)
O'Toole et al. 2019 Denmark mental disorder 129 54 (41.9%)
Sun et al. 2019 China diabetes 91 54 (59.3%)
Yu et al. 2019 China diabetes 185 70 (37.8%)
Total 8736 4006(45.86%)
Kristjánsdóttir et al. 2013a Norway pain 135 135 (100%)
Asklund et al. 2016a Sweden other 123 123 (100%)
Zairina et al. 2016a Australia respiratory and pulmonary disease 72 72 (100%)
Mackillop et al. 2018a UK diabetes 203 203 (100%)
Miremberg et al. 2018a Isreal diabetes 120 120 (100%)
Kim et al. 2018a Korea cancer patients 76 76 (100%)
Zhu et al. 2018a China cancer patients 114 114 (100%)
Park et al. 2019a Korea cancer patients 339 339 (100%)
Lee et al. 2019b Korea cancer patients 100 0 (0%)
Ginis et al. 2016 Belgium/Israel Parkinson's disease 38 NA (NA)
a study recruited only female participants.
b study recruited only male participants.
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recommend using existing reporting standards, such as the “Sex and
Gender Equity in Research” guidelines (SAGER) [43] or possibly even
going further and creating new sex and gender-sensitive standards for
digital health research in consideration of the specific practices in the
field.
5. Conclusion
Sex and gender are poorly considered and reported in mHealth/app-
based studies for chronic medical conditions. To effectively address the
specific health and preventative needs of mHealth users, sex and gender
should be systematically included in the research, development and
evaluation process of mHealth applications.
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